Product Information
CEVIMELINE HCL 30 MG CAPSULE is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $0.6871 per EA under NDC 63304047901. Its NADAC has been published 644 times since Nov 28, 2013.
Strength
30 mg/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
63304047901
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
CEVIMELINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA020989On Market Since
3/10/2016
Pharmacological Classes
Price Statistics
The NADAC for CEVIMELINE HCL 30 MG CAPSULE has been published 644 times since Nov 28, 2013, and over the history we have for it it has declined 68.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6871 per EA |
|---|---|
| All-time high | $2.2833 (Jan 15, 2014) |
| All-time low | $0.6268 (Nov 20, 2024) |
| 52-week high | $0.7172 |
| 52-week low | $0.6572 |
| Median price | $1.1541 |
| Average price | $1.2942 |
| Largest weekly change | +42.0% (Aug 17, 2022) |
| Weeks tracked | 644 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the Cevimeline market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of CEVIMELINE HCL 30 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for CEVIMELINE HCL 30 MG CAPSULE, manufactured by Sun Pharmaceutical Industries Inc., is $0.6871 per EA (NDC 63304047901), effective Jun 24, 2026.
How has the price of CEVIMELINE HCL 30 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has declined 68.1%. It has been tracked across 644 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CEVIMELINE HCL 30 MG CAPSULE?
Since Nov 28, 2013, the NADAC for CEVIMELINE HCL 30 MG CAPSULE has ranged from a low of $0.6268 (Nov 20, 2024) to a high of $2.2833 (Jan 15, 2014), with a median of $1.1541 per EA.
Are there cheaper alternatives to CEVIMELINE HCL 30 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of CEVIMELINE HCL 30 MG CAPSULE, so no direct lower-cost alternative is listed.
Who manufactures CEVIMELINE HCL 30 MG CAPSULE?
CEVIMELINE HCL 30 MG CAPSULE (NDC 63304047901) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.
Related Drugs
Same classification